Davis Polk advised the joint book-running managers in connection with the $80 million public offering of common stock of Dova Pharmaceuticals, Inc. The common stock is…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
